# Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

> **NCT00019383** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tyrosinase peptide
- **BIOLOGICAL:** tyrosinase-related protein-1

## Key facts

- **NCT ID:** NCT00019383
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019383, "Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00019383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*